GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2025

Jan 14, 2025

==> picture [93 x 59] intentionally omitted <==

ASX announcement

Genetic Technologies enters agreement to sell EasyDNA and AffinityDNA businesses and assets

Melbourne Australia, 15 January, 2025 : Genetic Technologies Limited (Administrators Appointed) (ASX:GTG) (“Genetic Technologies” or the “Company) advise that it has entered into an Asset Sale Agreement to sell the Company’s Direct-to-Consumer (DTC) Businesses and Assets.

The sale includes the Company’s rights, title and interest in:

• The businesses operating under the " EasyDNA ", " AffinityDNA ", " GTLDNA " HomeDNADirect ", " Who’z the Daddy ?" and " International Biosciences " brands (collectively the “ Businesses ”); and

• certain assets, including plant and equipment, selected supply chain contracts, intellectual property, the websites, phone numbers and social media accounts that are associated with the Businesses (collectively the “ Assets ”).

The sale is expected to complete by 20 January 2025. Further details in relation to the sale and transition arrangements will be provided on completion.

- END –

Authorised for release by the Administrators.

For inquiries, please contact:

Media	Security holders:
David Whitely
Strategic Communications	GeneticTechnologies@fticonsulting.com
+61 475 110 928
david.whitely@fticonsulting.com

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType™ and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

About EasyDNA

EasyDNA is an online provider of genetic testing services established in 2007 and developed into an online network of over 70 websites in over 42 countries. EasyDNA’s network of online retail sales platforms offers fast and affordable home DNA testing that is reliable and confidential. They also offer a number of lifestyle and health and wellbeing tests, and animal testing relating to allergies and tolerances. EasyDNA is a pioneering provider of genetic testing services, dedicated to delivering accurate and confidential results to individuals and organizations worldwide.

Forward Looking Statements

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forwardlooking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forwardlooking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.